{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:20:12Z","timestamp":1773282012214,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s12325-017-0593-9","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T06:45:51Z","timestamp":1500446751000},"page":"2033-2042","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study"],"prefix":"10.1007","volume":"34","author":[{"given":"Mark","family":"Fajgenbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8943-8209","authenticated-orcid":false,"given":"Ejaz","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"593_CR1","first-page":"844","volume":"82","author":"S Resnikoff","year":"2004","unstructured":"Resnikoff S, Pascolini D, Etya\u2019ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844\u201351.","journal-title":"Bull World Health Organ"},{"key":"593_CR2","unstructured":"RNIB. Number of adults and children certified with sight impairment and severe sight impairment in England and Wales: April 2011\u2013March 2012. \n                        http:\/\/www.rnib.org.uk\/aboutus\/Research\/reports\/otherresearch\/Pages\/sight_loss_statistics_report.aspx\n                        \n                    . Accessed 7 July 2015."},{"issue":"3","key":"593_CR3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"593_CR4","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268\u201379.","journal-title":"Arch Ophthalmol"},{"key":"593_CR5","first-page":"298","volume":"126","author":"Collaborative Normal Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal tension glaucoma. Am J Ophthalmol. 1998;126:298\u2013505.","journal-title":"Am J Ophthalmol"},{"key":"593_CR6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"The AGIS investigators","year":"2000","unstructured":"The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429\u201340.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"593_CR7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00347-005-1173-y","volume":"102","author":"J Wahl","year":"2005","unstructured":"Wahl J. Results of the Collaborative Initial Glaucoma Treatment Study (CIGTS). Ophthalmologe. 2005;102(3):222\u20136.","journal-title":"Ophthalmologe"},{"issue":"6","key":"593_CR8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701\u201313.","journal-title":"Arch Ophthalmol"},{"key":"593_CR9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/bjo.2005.076117","volume":"90","author":"FA Knox","year":"2006","unstructured":"Knox FA, Barry M, McGowan B, O\u2019Brien C. The rising cost of glaucoma drugs in Ireland 1996\u20132003. Br J Ophthalmol. 2006;90:162\u20135.","journal-title":"Br J Ophthalmol"},{"key":"593_CR10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/bjo.86.5.551","volume":"86","author":"DN Bateman","year":"2002","unstructured":"Bateman DN, Clark R, Azuara-Blanco A, Bain M, Forrest J. The effect of new topical treatments on the management of glaucoma in Scotland: an examination of ophthalmological health care. Br J Ophthalmol. 2002;86:551\u20134.","journal-title":"Br J Ophthalmol"},{"key":"593_CR11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.eye.6702593","volume":"22","author":"SM Macleod","year":"2008","unstructured":"Macleod SM, Clark R, Forrest J, Bain M, Bateman N, Azuara-Blanco A. A review of glaucoma treatment in Scotland 1994\u20132004. Eye. 2008;22:251\u20135.","journal-title":"Eye"},{"key":"593_CR12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/eye.2014.114","volume":"28","author":"AJ Connor","year":"2014","unstructured":"Connor AJ, Fraser SG. Glaucoma prescribing trends in England 2000 to 2012. Eye. 2014;28:863\u20139.","journal-title":"Eye"},{"issue":"1","key":"593_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"key":"593_CR14","unstructured":"EGS. European Glaucoma Society guidelines, 2008. \n                        http:\/\/www.eugs.org\/eng\/EGS_guidelines.asp\n                        \n                    . Accessed 7 July 2015."},{"issue":"3","key":"593_CR15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/08820538.2013.771198","volume":"28","author":"PA Newman-Casey","year":"2013","unstructured":"Newman-Casey PA, Weizer JS, Heisler M, et al. Systematic review of educational interventions to improve glaucoma medication adherence. Semin Ophthalmol. 2013;28(3):191\u2013201.","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"593_CR16","first-page":"190","volume":"17","author":"JC Tsai","year":"2006","unstructured":"Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006;17(2):190\u20135.","journal-title":"Curr Opin Ophthalmol"},{"issue":"12","key":"593_CR17","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/1060028014548569","volume":"48","author":"L Lin","year":"2014","unstructured":"Lin L, Zhao YJ, Chew PT, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014;48(12):1585\u201393.","journal-title":"Ann Pharmacother"},{"key":"593_CR18","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","volume":"29","author":"RD Fechtner","year":"2010","unstructured":"Fechtner RD. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618\u201321.","journal-title":"Cornea"},{"key":"593_CR19","doi-asserted-by":"crossref","unstructured":"Broadway DC et al. Adverse effects of topical antiglaucoma medication. Arch Ophthalmol. 1994;112:1437\u20131445.","DOI":"10.1001\/archopht.1994.01090230051020"},{"issue":"12","key":"593_CR20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2165\/00002512-200724120-00004","volume":"24","author":"AS Khouri","year":"2007","unstructured":"Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007;24(12):1007\u201316.","journal-title":"Drugs Aging"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0593-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0593-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0593-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T04:50:12Z","timestamp":1503291012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0593-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0593-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}